white → yellow1 → yellow2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
4-AcO-DiPT
3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate
4-Acetoxy-DiPT, Ipracetin, Iprocetyl, Aces, 4-Ace
4-AcO-DiPT is a synthetic psychedelic of the tryptamine class, first described by Alexander Shulgin by 2003 and encountered as a novel designer drug in 2005citation needed. It is thought to act primarily as a prodrug of 4-HO-DiPT. The substance is notable for producing a unique combination of physical euphoria and stimulation alongside atypically minimal visual and introspective psychedelic effects compared to related tryptamines.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~3 mg
Light5-10 mg
Moderate10-20 mg
Strong20-35 mg
Heavy35+ mg
4-AcO-DiPT occurs as both a hydrochloride salt and a freebase. The freebase is roughly 10% more potent by weight than the equivalent mass of the HCl salt.
Duration
Onset15-40 minutes
Come Up20-40 minutes
Peak1.5-2 hours
Offset1-1.5 hours
After Effects2-6 hours
Total3-4 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Analysis enhancementConceptual thinkingCreativity enhancementDelusionsEmotion enhancementImmersion enhancementMemory suppressionMindfulnessNovelty enhancementPersonal bias suppressionSpirituality enhancementThought accelerationThought disorganizationThought loopsTime distortionUnity and interconnectednessWakefulnessEgo death
Visual
Auditory
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
4-AcO-DiPT acts as a serotonin 5-HT2 receptor agonist, likely functioning as a partial agonist at the 5-HT2A receptor specifically.1 Its psychedelic effects are believed to stem primarily from this 5-HT2A activity, consistent with the head-twitch response it produces in rodents (a behavioral proxy for psychedelic activity).1 Its direct potency at 5-HT2 receptors is considerably reduced relative to 4-HO-DiPT.citation needed Additional serotonin receptors may contribute to its overall effects, though very little pharmacological data currently exists for this substance.
Pharmacokinetics
4-AcO-DiPT is thought to function primarily as a prodrug of 4-HO-DiPT, undergoing deacetylation in the body in a manner analogous to the conversion of psilocybin to psilocin.citation needed This prodrug relationship has not yet been confirmed through formal pharmacokinetic studies, and very little data exists regarding the metabolism or pharmacokinetic properties of this substance.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects develops almost immediately after ingestion.
Baseline Reset
7 days in the absence of further consumption
Half Tolerance
Approximately 3 days
Cross Tolerance
Psychedelics (all psychedelics will have a reduced effect following 4-AcO-DiPT consumption)
Harm Potential
Addiction & Dependence
Psychological
LowNot generally habit-forming and the desire to use it can decrease with repeated use; however, compulsive redosing is atypically prominent for a psychedelic tryptamine, likely due to its short duration, hedonic effects, and rapid onset/offset profile. May possess higher liability for frequent consumption relative to most psychedelics.
Psychosis Risk
Risk of adverse psychological reactions including psychosis is noted primarily in combination with other substances such as cannabis, lithium, or stimulants; psychosis from the substance alone is not well-documented. As with other psychedelics, risk increases with higher doses.citation needed
Seizure Risk
Described as a likely rare effect that may occur in predisposed individuals, especially under physically taxing conditions such as dehydration, fatigue, or undernourishment. No documented cases of seizures have been reported with this compound alone.
History & Culture
4-AcO-DiPT was first characterized in the scientific literature by Alexander Shulgin, with documentation appearing by 2003. The compound appears in TiHKAL (Tryptamines I Have Known and Loved), Shulgin's comprehensive reference work on tryptamine compounds co-authored with Ann Shulgin.…
Legality
By Country
Illegal10
DenmarkIllegal (analog/blanket ban)Bekendtgørelse om euforiserende stoffer (bekendtgørelse nr. 405 af 26. marts 2026)2
Listed as a Schedule B controlled substance under Danish drug control legislation.
GermanyIllegal (analog/blanket ban)
IrelandIllegalMisuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022)11
4-AcO-DiPT is a designated controlled drug in Ireland as an ester of the Schedule 1 ring-hydroxytryptamine class. Its manufacture, production, preparation, sale, supply, distribution and possession are unlawful except for the specified research and other special purposes, subject to the applicable licence or authority.
ItalyIllegal (analog/blanket ban)Italy’s Consolidated Law on Narcotic Drugs and Psychotropic Substances places tryptamine-derived indoles that have hallucinogenic effects or can cause sensory distortions in tabella I. 4-AcO-DiPT is covered by that class provision as a tryptamine-derived indole; all forms, products, mixtures, and mixes of substances in tables I and II are subject to the law. Unauthorized production, manufacture, sale, distribution, transport, import, export, acquisition, receipt, or possession for non-exclusively personal use of a tabella I substance is criminally punishable under Article 73.
JapanIllegalThe exact identity is expressly named in the current MHLW designated-drug list, including its salts. 4-AcO-DIPT is a designated drug, not a named narcotic. Ordinary possession, sale, import, manufacture, transfer and use are prohibited outside legally defined medical or other permitted uses.
NorwayIllegal4-AcO-DiPT is listed as a narcotic in Norway's Narkotikalisten, the list annexed to the Narkotikaforskriften. The regulation prohibits possession, use, manufacture, acquisition, sale, dispatch, import, export, and storage of narcotics without lawful authority.
SingaporeIllegalMisuse of Drugs Act 197318
Singapore lists 4-Acetoxy-N,N-diisopropyltryptamine (4-Acetoxy-DiPT or 4-AcO-DiPT) as a Class A drug in the First Schedule to the Misuse of Drugs Act 1973. The Act defines substances in Part 1 of that Schedule as controlled drugs.
SwedenIllegal
SwitzerlandIllegalBetmVV-EDI (SR 812.121.11), Annex 6 Verzeichnis e item 80, read with BetmG (SR 812.121) Articles 7 and 20(1)(c)212223
4-AcO-DiPT is expressly named, not merely covered by a generic tryptamine class. The current Swiss ordinance treats Annex 6/list e entries as controlled substances/products with presumed narcotic-like effects. Unauthorized cultivation, manufacture, import/export, storage, use, or marketing is punishable under the Article 7 authorization regime and Article 20(1)(c); this is a prohibited controlled-substance classification, subject to any applicable statutory authorization.
Controlled / restricted2
United StatesRestrictedFederal Controlled Substances Act, 21 U.S.C. §§ 802(32)(A), 812(c), 813; DEA Diversion Control Division Controlled Substance Schedules and August 2026 Orange Book; Alabama Administrative Code Chapter 420-7-2-A; North Carolina General Statutes § 90-89(3)(nn); West Virginia Code § 60A-2-204(d); South Dakota Codified Law § 34-20B-14(59)25262728293031323334
At the federal named-list level, DEA's current controlled-substance schedules and 21 U.S.C. § 812(c) do not expressly name 4-AcO-DiPT; the nearby 5-MeO-DIPT and 5-MeO-DMT entries are distinct compounds. That federal omission is not a nationwide unscheduled or general-lawfulness finding: DEA says its lists are non-comprehensive, and the Federal Analogue Act can apply only if the statutory substantial-chemical-similarity and effect/representation requirements are met and the substance is intended for human consumption under 21 U.S.C. §§ 802(32)(A), 813. Alabama and West Virginia control 4-AcO-DiPT in Schedule I by express name, while North Carolina and South Dakota control it through substituted-tryptamine provisions. Application of the federal analogue provisions depends on whether the statutory elements are met for the particular sample or transaction. These four state controls apply only in Alabama, West Virginia, North Carolina and South Dakota.
FinlandRestrictedNarcotics Act 373/2008, §§ 3(1)(5)(e), 3(2), 5(2) and 48; Government Decree 1130/2014 on psychoactive substances banned from the consumer market, current annex as consolidated 25 June 2026 and amended by Decree 650/2026; Criminal Code 39/1889, chapter 44 § 5a.34567
4-AcO-DiPT is expressly named in Finland's current consumer-market-banned psychoactive-substance annex, so it falls into the consumer-market-banned psychoactive-substance category rather than a narcotic-schedule or generic analogue classification. The current control prohibits manufacture, import, storage, offering for sale and transfer, with statutory research and industrial exceptions. The current narcotics schedule's generic ester/isomer clauses apply to substances in the relevant schedule; its named indole/tryptamine entries include DET, DMT, Etryptamine, psilocin and psilocybin, but not 4-HO-DiPT (the relevant parent alcohol) or 4-AcO-DIPT, so those clauses do not supply narcotic scheduling for this compound. Section 5(2) does not itself state the blanket possession/use prohibition applicable to narcotics under section 5(1). Current Narcotics Act section 48 cross-references Criminal Code chapter 44 section 5a. The instruments do not separately address medicines, positional isomers, unlisted analogues, or fact-specific exceptions.
References
Source Pages
Citations
- Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, & Halberstadt AL. (April 2021). Investigation of the Structure-Activity Relationships of Psilocybin Analogues. ACS Pharmacology & Translational Science, 4(2), 533–542. https://doi.org/10.1021/acsptsci.0c00176123
- Bekendtgørelse om euforiserende stoffer (bekendtgørelse nr. 405 af 26. marts 2026). retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2026/405/pdf1
- Finlex current consolidated annex to Government Decree 1130/2014, as amended by Decree 650/2026. opendata.finlex.fi (n.d.). https://opendata.finlex.fi/finlex/avoindata/v1/akn/fi/act/statute-consolidated/2014/1130/fin%40latest/media/8500.pdf1
- Finlex current consolidated Government Decree 1130/2014. opendata.finlex.fi (n.d.). https://opendata.finlex.fi/finlex/avoindata/v1/akn/fi/act/statute-consolidated/2014/1130/fin%40latest1
- Finlex current consolidated Narcotics Act 373/2008, section 3. opendata.finlex.fi (n.d.). https://opendata.finlex.fi/finlex/avoindata/v1/akn/fi/act/statute-consolidated/2008/373/fin%40latest1
- Finlex current consolidated Government Decree 543/2008 on substances, preparations and plants considered narcotics. opendata.finlex.fi (n.d.). https://opendata.finlex.fi/finlex/avoindata/v1/akn/fi/act/statute-consolidated/2008/543/fin%40latest1
- Finlex current consolidated Criminal Code 39/1889, chapter 44 section 5a. opendata.finlex.fi (n.d.). https://opendata.finlex.fi/finlex/avoindata/v1/akn/fi/act/statute-consolidated/1889/39-001/fin%40latest1
- Neue-psychoaktive-Stoffe-Gesetz, Anlage 1 Nr. 5.1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- § 4 NpSG. gesetze-im-internet.de (2019). https://www.gesetze-im-internet.de/npsg/__4.html12
- Anlage zum Neue-psychoaktive-Stoffe-Gesetz (NpSG Anlage). Bundesministerium der Justiz (2019). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-AcO-DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.